With regard to Health Canada's approval to Mylan Pharmaceuticals to produce a generic Suboxone treatment: (a) what frameworks exist to ensure that pharmaceutical companies whose drugs are granted approval for use in Canada conduct business in a way that is responsible and accountable to Canadians; (b) does the Department have a framework in place to properly screen for, and assess, conflicts of interest involving manufacturers of prescription drugs that produce both an addictive medication as well as producing its addictive treatment, and, if so, can the department withdraw an approval until the conflict of interest is resolved; and (c) will the Minister of Health ensure that no pharmaceutical company is permitted to bill taxpayers for both a highly addictive drug, and the treatment for the addiction that can result?
In the House of Commons on March 24th, 2014. See this statement in context.